Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature

BACKGROUND Glioblastoma is the most common type of brain tumor and is invariably fatal,with a mean survival time of 8-15 mo for recently diagnosed tumors,and a 5-year survival rate of only 7.2%.The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide.However,the prognosis remains poor and longterm survival is rare.This report aimed to demonstrate a new therapeutic strategy for the treatment of glioblastoma.CASE SUMMARY A patient was referred to the Department of Neurosurgery with an intracranial space-occupying lesion with a maximum diameter of approximately 5 cm.The tumor was compressing functional areas,and the patient accordingly underwent partial resection and concurrent chemoradiotherapy.The imaging and pathological findings were consistent with a diagnosis of glioblastoma with oligodendroglioma differentiation(World Health Organization IV).The patient was finally diagnosed with glioblastoma.However,the patient discontinued treatment due to intolerable side effects,and was prescribed Kangliu pill(KLP)7.5 g three times/d,which he has continued to date.Significant shrinkage of the tumor(maximum diameter reduced from about 3.5 to about 2 cm)was found after 3 mo of KLP therapy,and the tumor was further reduced to about 1 cm after 3 years.The patient’s symptoms of headache,limb weakness,and left hemiplegia were relieved,with no side effects.CONCLUSION KLP has been a successful intervention for glioblastoma, and the current caseindicates that traditional Chinese medicine may offer effective alternativetherapies for glioblastoma.

A clinical protocol: A double-blinded, randomized controlled trial on the effect of traditional Chinese medicine formula Shoutai Pill in the treatment of threatened abortion

for about 20%of all clinically confirmed pregnancy.It is the main cause of early abortion.Vaginal bleeding is the main clinical manifestation,which seriously affects the mental health and quality of life of pregnant women.Currently,there is effective treatment for this condition.A recent meta-analysis showed that Shoutai Pill(ST Pill),a traditional Chinese medicine(TCM)formula,can effectively decrease the rate of threatened abortion.However,high heterogeneity was found among the studies included in the meta-analysis,this conclusion on the efficacy of TCM is not definitive.Although several have been conducted,some of them do not describe randomization and blinding methods.To address these problems,this article proposes an improved clinical treatment scheme based on ST Pill,which is to be tested through a well-designed randomized controlled trial,for the treatment of threatened abortion.Methods:This is a double-blinded,randomized,placebo-controlled trial to be conducted in a public Three-A hospital in China's Mainland.A total of 200 people will be enrolled.Using computer-generated random numbers,the participants will be randomly divided into two groups at a ratio of 1:1(treatment group(treated with ST Pill group)and placebo group).Both groups will receive medication to the end of the 20th gestational week or 1 week after vaginal bleeding stops,depending on which is longer.Participants in the treatment group will be treated with ST Pill(20 pills/time,once a day),and those in the placebo group will receive a placebo drug which is similar in appearance and smell with ST Pill.The main observation index is the live birth rate.Discussion:Although the efficacy of ST Pill in threatened abortion is well-known,no study has tested its efficacy through a double-blinded,randomized trials.Therefore,there is an urgent need for a standardized randomized double-blinded controlled trial to evaluate the clinical efficacy of ST Pill.ST Pill is likely to be a convenient and effective TCM pill for the prevention of threatened abortion.

Can Tibetan medicine Honghua Ruyi pills relieve endometriosisassociated dysmenorrhea?Protocol for a randomized placebocontrolled trial

Objective:To provide high-quality clinical evidence of the efficacy of Tibetan medicine Honghua Ruyi(HHRY)pills for endometriosis-associated dysmenorrhea.Methods:This study constitutes a multicenter,randomized,double-blind,placebo-controlled trial encompassing a three-menstrual cycle intervention followed by a three-menstrual cycle follow-up period.A total of 164 eligible females with endometriosis-associated dysmenorrhea were randomly divided into HHRY pills and placebo groups in a 1:1 ratio.The primary outcome included dysmenorrhea symptoms assessed using Visual Analog Scale(VAS)scores and quality of life,whereas the secondary outcome measures included the maximum VAS for non-menstrual pelvic pain,duration of pain episodes(in days),frequency and quantity of the consumption of ibuprofen sustained-release capsules(or other non-steroidal anti-inflammatory drugs),and days off work/study for staff/student due to dysmenorrhea,ovarian cyst,and/or pelvic nodule size.The safety was monitored throughout the treatment period.All the analyses were based on the intention-to-treat principle.For continuous outcomes,simple or multiple linear regressions were used to estimate the differences between the HHRY pills and placebo groups,with categorical data expressed as the number and percentage of occurrences.Differences were compared using the chi-square test or Fisher's exact test.The predefined analysis was adjusted for concomitant treatment,a variable considered to be associated with outcomes but unaffected by treatment allocation.Estimates of treatment effects were reported with 95%confidence intervals.Two-tailed P values≤.05 were considered statistically significant.Conclusion:Positive results from this trial,upon completion would provide robust evidence for the efficacy and safety of HHRY pills in treating dysmenorrhea in patients with endometriosis.

Clinical Efficacy and Therapeutic Mechanisms of Traditional Chinese Medicine for Neuroprotection and Neurogenesis in Stroke Treatment

Stroke is the leading cause of human disability with limited effective drugs availability. The disruption of multiple signaling pathways in stroke makes developing new drugs be difficult. Traditional Chinese medicine(TCM) has its unique advantage in targeting multiple signaling pathways with multiple components. Many TCM formulas have the potential for neuroprotection and neurogenesis, but well-designed clinical trials are insufficient and underlying mechanisms unclear. Herein, we introduce the commonly used TCM formulas for stroke treatment and selectively introduce two classic formulas, An Gong Niu Huang(AGNH) pill and Bu Yang Huan Wu Decoction(BYHWD) for neuroprotection and neurogenesis, respectively. Current scientific evidence and clinical trials indicate AGNH pill could be an effective neuroprotective formula as adjunct therapy with relative safety. On the other hand, as a representative TCM formula for post stroke disability, BYHWD could improve the neurological outcome with its neuroprotective and neurogenic effects. The underlying mechanisms could be attributed to the modulation of multiple molecular targets with its multiple components. In conclusion, TCM formulas could be potential adjunct therapies for stroke treatment. The clinical efficacies and molecular mechanisms of promoting neuroprotection and neurogenesis remain to be further studies.

Efficacy and safety of oral Chinese patent medicine combined with sacubitril/valsartan in the treatment of chronic heart failure:A Metaanalysis

Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.

Exploring the molecular mechanism of Suoquan pill in the treatment of diabetic kidney disease based on network pharmacology,molecular docking,in vitro experiment

Background:Diabetic kidney disease(DKD)is a microvascular complication of diabetes mellitus and is the main cause of end-stage renal failure.Suoquan pills(SQP)has a variety of pharmacological activities and multiple therapeutic effects,and it is used clinically as a basic formula for the treatment of DKD.Methods:Public databases were used to identify SQP compounds and the potential targets of SQP and DKD.A drug-component-therapeutic target network was constructed.Protein-protein interaction network analysis,Gene Ontology functional analysis,and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were used to analyse the potential molecular mechanisms of SQP based on common targets of drugs and diseases.Molecular docking simulations were conducted to confirm the binding abity of the core compounds to key targets.The efficacy and predicted molecular mechanisms of SQP were validated using cell counting kit-8 assay,flow cytometry,and western blotting with HK-2 cells as a model.Results:Network pharmacology analysis showed that 26 compounds and 207 potential targets of SQP were involved in the treatment of DKD;boldine,denudatin B,pinocembrin,kaempferoid,and quercetin were considered core compounds,and epidermal growth factor receptor(EGFR)and proto-oncogene,non-receptor tyrosine kinase(SRC)were considered key targets.Gene Ontology enrichment analysis indicated that protein phosphorylation and negative regulation of apoptotic processes are important biological processes in the treatment of DKD by SQP.Molecular docking confirmed the excellent binding abilities of boldine,denudatin B,kaempferide,and quercetin to EGFR and SRC.The results of in vitro experiments showed that treatment with an ethanolic extract of SQP significantly protected HK-2 cells from high glucose-induced cell damage.In addition,the SQP ethanol extract inhibited the phosphorylation of EGFR and SRC,suppressed the apoptosis rate,and regulated apoptosis-related proteins in HK-2 cells under high glucose stress.Conclusion:This study systematically and intuitively illustrated the possible pharmacological mechanisms of SQP against DKD through multiple components,targets,and signalling pathways,especially the inhibition of EGFR and SRC phosphorylation and apoptosis.

Clinical efficacy of Baijin pills in the treatment of generalized tonicclonic seizure epilepsy with cognitive impairment

BACKGROUND The generalized tonic-clonic seizure(GTCS)is the most usual variety of epileptic seizure.It is mainly characterized by strong body muscle rigidity,loss of consciousness,a disorder of plant neurofunction,and significant damage to cognitive function.The effect of antiepileptic drugs on cognition should also be considered.At present,there is no effective treatment for patients with epilepsy,but traditional Chinese medicine has shown a significant effect on chronic disease with fewer harmful side effects and should,therefore,be considered for the therapy means of epilepsy with cognitive dysfunction.AIM To investigate the clinical efficacy of Baijin pills for treating GTCS patients with cognitive impairment.METHODS This prospective study enrolled patients diagnosed with GTCS between January 2020 and December 2023 and separate them into two groups(experimental and control)using random number table method.The control group was treated with sodium valproate,and the experimental group was Baijin pills and sodium valproate for three months.The frequency and duration of each seizure,the Montreal Cognitive Assessment Scale(MoCA),and the Quality of Life Rating Scale(QOLIE-31)were recorded before and after treatment.RESULTS There were 85 patients included(42 in the control group and 43 in the experimental group).After treatment,the seizure frequency in the experimental group was significantly reduced(P<0.05),and seizure duration was shortened(P<0.01).The total MoCA score in the experimental group significantly increased compared to before treatment(P<0.01),and the sub-item scores,except naming and abstract generalization ability,significantly increased(P<0.05),whereas the total MoCA score in the control group significantly decreased after treatment(P<0.05).The QOLIE-31 score of the experimental group increased significantly after treatment compared to before treatment(P<0.01).CONCLUSION Baijin pills have a good clinical effect on epilepsy with cognitive dysfunction.

Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill(定坤丹):A Randomized Controlled Clinical Trial

Objective: To assess the ef?cacy and safety of the Chinese medicine Dingkun Pill(定坤丹,DKP) on insulin resistance in women with polycystic ovary syndrome(PCOS).Methods: A total of 117 women with PCOS were randomly assigned to Group A(38 women),Group B(40 women),or Group C(39 women) in a randomization sequence with SAS software and a 1:1:1 allocation ratio using random block sizes of 6,and were given 7 g of oral DKP daily(Group A),1 tablet of Diane-35 orally daily(Group B),or 7 g of oral DKP daily plus 1 tablet of Diane-35 orally daily(Group C).Patients took all drugs cyclically for 21 consecutive days,followed by 7 drug-free days.The treatment course for the 3 groups was continued for 3 consecutive months.Oral glucose tolerance tests(OGTT)were performed before treatment and again after 2 and 3 months of therapy,respectively,and homeostasis model assessment for insulin resistance(HOMA-IR) and quantitative insulin sensitivity check index(QUICKI) were calculated.Results: Of 117 women with PCOS,110 completed the entire course of therapy: 35 in Group A,36 in Group B,and 39 in Group C.After treatment,all three groups showed signi?cant decreases in fasting glucose: at1 h glucose decreased signi?cantly in Group A(by 0.5±1.4 mmol/L,P=0.028) and Group C(by 0.5±1.2 mmol/L,P=0.045); while showing a tendency to increase in Group B(by 0.4±1.9 mmol/L,P=0.238).HOMA-IR decreased signi?cantly in Group C [by 0.5(–2.2 to 0.5) m IU mmol/L2,P=0.034].QUICKI was signi?cantly increased in Groups A and C(by 0.009±0.02,P=0.033 and by 0.009±0.027,P=0.049,respectively),while no change was observed in Group B.Repeated-measure ANOVA showed that the absolute changes in all parameters(except for glucose at1 h),including glucose and insulin levels at all time-points during OGTT and in HbA1 c,HOMA-IR,and QUICKI,were not signi?cantly different among the 3 groups after treatment(P>0.05).Conclusion: DKP or DKP combined with Diane-35 produce a slight improvement in insulin sensitivity compared with Diane-35 alone in PCOS patients(Trial Registration: Clinical Trials.gov,NCT03264638).

Are the release characteristics of Erzhi pills in line with traditional Chinese medicine theory?A quantitative study

Objective:Traditional Chinese medicine(TCM)has been widely used throughout China to prevent and cure diseases for thousands of years,and now it is a part of the integrative medicine field that is available in Western societies.To ensure the safety and quality of the herbal medicines that are a major part of the TCM tradition,they must be held to modern pharmaceutical standards.Erzhi pill(EZP)is a Chinese Pharmacopeia-listed herbal preparation that is used in the long-term clinical management of postmenopausal symptoms,osteoporosis and menstrual disorders.Until now,whether the drug release mechanism of EZP is in line with its intended TCM usage has not been studied.Methods:The release of specnuezhenide from three EZPs(self-made,Leiyunshang and Renhe)in simulated gastric fluid(SGF),acetate buffer(p H 4.5 buffer)and simulated intestinal fluid(SIF)was investigated in a dissolution test.The water uptake capacity and erosion extent of the three EZPs were investigated using swelling and erosion studies.The drug release mechanism was further assessed through statistical model fitting,using DDSolver software.Results:The release of specnuezhenide from all three EZPs in SGF was less than 50%within a 4 h period.However,over 70%of the specnuezhenide was released from each EZP in both p H 4.5 buffer and SIF in the same time.Analysis of the swelling and erosion behaviors and the drug release mechanism of the three EZPs confirmed that the release rate from EZP followed a sustained release profile,which was an interactive combination of swelling and erosion.Conclusion:This study showed that the release pattern from the pills was in line with the intended TCM use of EZP.TCM had not only theoretically considered sustained release from the pills,but also formulated them to achieve this release pattern.When establishing quality control standards for pills,the theoretical TCM usage and the actual release patterns need to be considered.

AMELIORATING EFFECTS OF CARDIOTONIC PILLS,A COMPOUND CHINESE MEDICINE ON MYOCARDIAL MICROCIRCULATORY DISTURBANCE AND MYOCARDIAL INJURY AFTER ISCHEMIA-REPERFUSION

Cardiotonic Pills(CP)is a compound preparation of Chinese medicine consisting of Salvia miltiorrhiza,Panax notoginseng and Borneol,and it has been approved in 1994by the China State Food and Drug Administration for treating ischemic angina pectoris.It has passed the Phase II clinical trials by the US Food and Drug Administration in2009,December,demonstrating its potential to prolong

Xiaoyao pill for treatment of functional dyspepsia in perimenopausal women with depression

AIM: To evaluate the efficacy and safety of the Xiaoyao pill for treatment of functional dyspepsia (FD) associated with perimenopausal depression.

Effect of <i>Qing’e Pill</i>plus <i>Salvia</i>on Non-Traumatic Osteonecrosis of the Femoral Head of Idiopathic Type in Earlier Stage: A Case Report of a Twelve-Month of Period

Background: Compromised circulatory and bone/lipid metabolic dysfunction are two major contributors to non-traumatic osteonecrosis of the femoral head (ONFH). Qing’e pill plus Salvia has significant anti-inflammatory and anti-atherosclerotic action, and it could also regulate bone formation and remodeling by suppressing osteoclasts. Case Report: We describe a case of a 62-year- old man with ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents for past 3 years. After six months treatment with Qing’e pill plus Salvia, the plasma low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1 (apo A1), apolipoprotein B (apo B), total cholesterol (TC), triglycerides (TG), and blood viscosity were measured on an empty stomach. The Harris scores were maintained during a six months follow-up after discontinuation of Qing’e pill plus Salvia. Discussion: Our case has shown that plasma levels of inflammatory and atherosclerotic relaxed factors and the Harris scores may be controlled with herbal medication in ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents.

Effects and mechanisms of traditional Chinese medicines on functional dyspepsia: A review

Functional dyspepsia(FD) is a common and frequently occurring disease in clinic. With the infuence of environmental factors, social factors and dietary factors, the incidence rate of FD in the general population is yearly increasing. Traditional Chinese medicine has a long history and far-reaching infuence in the treatment of FD. It can prevent and treat FD in the form of multiple-components, targets and channels,with obvious effect and prominent advantages. This article starts with the common syndrome types of FD, and discusses the research progress of single Chinese medicine, effective ingredients and the mechanism of traditional Chinese medicines in treating FD, in order to provide a theoretical basis for the treatment of FD with traditional Chinese medicines.

Efficacy of Xianglian pill for antibiotic-associated diarrhea: a protocol for systematic review and meta-analysis

Background:Antibiotic-associated diarrhea is a clinical common symptom of antibiotics overuse and occurs in 5%-70%of adults.Xianglian pill has been traditionally considered as an efficient treatment of diarrhea and gastrointestinal diseases for thousands of years.However,no systematic review and meta-analyses have focused on its positive effects.Hence,this protocol for systematic review and meta-analysis was developed to evaluate the effect and clinical safety of Xianglian pill on treating antibiotic-associated diarrhea.Methods:All randomized controlled trials published in Chinese and English and assessed use of Xianglian pill for antibiotic-associated diarrhea will be included.Databases of PubMed,EMBASE,Cochrane Library,China National Knowledge Infrastructure,Chinese Biomedical Literature,Wanfang,and Chinese Science and Technology Periodical Database will be searched for randomized controlled trials from their inception until November 16,2020.Primary outcomes will be the incidence of diarrhea and adverse events,and secondary outcomes will be bowel movements and microbiome characteristics.Two authors will extract data and assess the risk of bias independently.Risk ratio will be used to evaluate the results,and meta-analyses will be conducted using STATA 15.0 software.The review aims to demonstrate the effectiveness of Xianglian pill in the prevention and treatment of antibiotic-associated diarrhea.

A Report of 10 Cases of Parkinson’s Disease Cured by Xifengzhizhan Pills and Xifengzhizhan Capsules

Parkinson’s Disease (PD) is a chronic progressive degeneration disease of the central nervous system of extrapyramidal system. The main pathological changes are the degeneration of the substantia nigra striatum, lack of dopamine in the brain, causing clinical performance: static tremor, muscle rigidity, slow movement and abnormal posture. It is one of the worldwide medical problems;at present, modern medicine thinks that PD is an incurable and permanent disease. However, in my long-term clinical work, I have cured many cases of PD patients by using Xifengzhizhan pills and Xifenzhizhan capsules, and I have found and proved that Chinese Medicine can cure PD.

左归丸联合丁苯酞佐治帕金森病轻度认知障碍疗效评价

目的探讨左归丸联合丁苯酞佐治帕金森病轻度认知障碍的临床疗效。方法选取医院2023年1月至3月收治的帕金森病轻度认知障碍患者80例,按随机数字表法分为观察组和对照组,各40例。两组患者均予常规抗帕金森病西药治疗,并予丁苯酞软胶囊口服,观察组患者加服左归丸。两组均连续治疗8周。结果观察组总有效率为90.00%,显著高于对照组的70.00%(P<0.05)。治疗后,观察组患者的腰膝酸软、胁肋疼痛、头晕头痛中医证候积分均显著低于对照组(P<0.05);观察组患者的沉默信息调节因子1(SIRT1)蛋白表达水平显著高于对照组,核因子κB(NF-κB)蛋白表达水平显著低于对照组(P<0.05);观察组患者的蒙特利尔认知评估量表(MoCA)、简易精神状态量表(MMSE)及日常生活活动能力(ADL)量表评分均显著高于对照组(P<0.05);观察组患者的统一帕金森病评定量表(UPDRS)评分显著低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(5.00%比2.50%,P>0.05)。结论常规抗帕金森病治疗基础上佐以左归丸联合丁苯酞,可降低帕金森病轻度认知障碍患者的中医证候积分,改善SIRT1及NF-κB蛋白表达水平,提升认知功能及日常生活能力。

抵挡汤合寿胎丸加减治疗不全流产临床观察

目的观察抵挡汤合寿胎丸加减治疗不全流产的临床疗效。方法将60例不全流产患者按照随机数字表法分为2组,对照组30例予米非司酮片联合产妇安颗粒治疗,治疗组30例予米非司酮片联合抵挡汤合寿胎丸加减治疗,2组均连用2周,随访3个月经周期。比较2组治疗1、2周疗效;比较2组阴道出血时间、月经复潮时间;比较2组治疗1周后血清人绒毛膜促性腺激素(β-HCG)水平变化;比较2组治疗前后子宫内膜厚度、子宫动脉血流参数变化;比较2组治疗前、随访时月经量评分、症状评分变化。结果治疗组治疗1周有效率86.7%(26/30),对照组治疗1周有效率70.0%(21/30),治疗组治疗1周疗效优于对照组(P<0.05)。治疗组治疗2周总有效率100%(30/30),对照组治疗2周总有效率96.7%(29/30),2组治疗2周疗效比较差异无统计学意义(P>0.05)。治疗组阴道出血时间少于对照组(P<0.05);2组月经复潮时间均推后,比较差异无统计学意义(P>0.05)。2组平均血清β-HCG水平比较差异无统计学意义(P>0.05)。治疗1周后2组子宫内膜厚度比较差异无统计学意义(P>0.05);治疗2周后2组子宫内膜厚度均较本组治疗1周后增加(P<0.05),治疗组治疗2周后子宫内膜厚度大于对照组(P<0.05)。2组治疗后子宫动脉血流阻力指数(RI)、子宫动脉搏动指数(PI)、螺旋动脉收缩期峰值流速/舒张末期峰值流速(S/D)水平均较本组治疗前改善(P<0.05);治疗后治疗组RI、PI、S/D改善均优于对照组(P<0.05)。治疗组治疗前与随访时月经量评分比较差异无统计学意义(P>0.05);对照组随访时月经量评分较本组治疗前减少(P<0.05);2组随访时月经量评分比较差异有统计学意义(P<0.05)。与本组治疗前比较,随访时治疗组小腹胀痛、腰骶酸痛、乳房胀痛评分和总评分降低(P<0.05),对照组小腹胀痛、腰骶酸痛、月经后期评分和总评分升高(P<0.05);2组随访时小腹胀痛、腰骶酸痛、月经后期评分和总评分比较差异均有统计学意义(P<0.05)。结论抵挡汤合寿胎丸加减治疗不全流产,可缩短阴道出血时间,降低血清β-HCG水平,促进子宫内膜修复,改善子宫动脉血流参数。

化瘀丸治疗中晚期恶性肿瘤患者血液高凝状态的临床研究

目的:探讨化瘀丸治疗中晚期恶性肿瘤患者血液高凝状态的临床疗效和安全性。方法:选取2018年6月至2021年12月北京中医医院肿瘤科门诊和病房的中晚期恶性肿瘤血液高凝状态患者72例作为研究对象。采用前瞻性队列研究,根据是否应用化瘀丸分为观察组(n=35)和对照组(n=37)。对照组接受必要的物理对症支持治疗,观察组在对照组基础上口服化瘀丸8周,2组共随访24周。观察2组患者的血液高凝状态改善率、凝血指标变化、中医证候积分、静脉血栓栓塞(VTE)大出血发生,以及不良事件发生情况。结果:4周后,观察组血液高凝状态改善率为43.75%,对照组为29.41%(P>0.05);8周后,观察组血液高凝状态改善率为65.63%,对照组为41.18%(P<0.05)。进一步分析凝血相关指标变化,发现4周和8周后观察组血浆纤维蛋白原(FIB)低于对照组(P<0.05)。观察组患者中医证候积分改善的总有效率为50.00%,对照组为14.81%(P<0.05),2组患者均未出现大出血情况,观察组未发生药物相关不良事件。结论:化瘀丸可以在必要的物理支持治疗外,进一步改善中晚期恶性肿瘤患者血液高凝状态,缓解血瘀证相关症状。

颈椎康复丸治疗蛋白聚糖诱导小鼠骨关节炎研究

目的研究中药复方颈椎康复丸治疗蛋白聚糖诱导小鼠骨关节炎的影响,为扩大该药的适应证及临床应用提供参考。方法采用Balb/c小鼠进行实验,将小鼠随机分为正常组,模型组,颈椎康复丸高、低剂量(6、3 g·kg^(-1)·d^(-1))组。全部小鼠(正常组除外)腹腔注射0.2 mL DDA佐剂(含100μg蛋白聚糖)造模;正常组给予0.2 mL生理盐水。首次免疫后,每隔2周进行关节炎评估和体重监测直到第14周。应用HE染色和番红固绿染色观察关节组织病理形态。应用ELISA法测定小鼠血清炎症因子IL-1β、IL-6、TNF-α和IL-17A。结果颈椎康复丸对小鼠骨关节炎有明显的抑制作用,能降低关节炎性评分和肿胀度。镜下观察,颈椎康复丸能保护小鼠关节组织,减少炎性浸润。颈椎康复丸能降低小鼠血清中炎症因子IL-1β、IL-6、TNF-α和IL-17A水平。结论颈椎康复丸对蛋白聚糖诱导的小鼠骨关节炎有改善作用。

中医护理方案在青少年低度近视中的效果评价

目的评价对青少年低度近视实施中医护理方案的效果。方法选取2022年3月—2022年11月在中国中医科学院眼科医院眼科门诊就诊的青少年低度近视患儿130例(260只眼),随机分为对照组和观察组,各65例(130只眼)。对照组予常规护理和框架眼镜矫正,观察组在对照组的基础上给予中医护理方案干预,包括耳穴压丸、梅花针、眼部刮痧及个性化健康教育,每周2次,连续干预3个月。干预前及干预后分别填写《中小学生近视一般状况调查问卷》,观察患者用眼健康行为变化,采用近视疾病相关知识及预防保健知识答题评估近视知识掌握程度,检查患者裸眼视力和屈光度,进行统计学分析。结果(1)用眼健康行为:观察组干预后的每日户外活动时间高于对照组(t=3.018,P=0.003),每次使用电子产品的时间(t=2.822,P=0.006)、每日持续近距离读写的时间(t=2.648,P=0.009)、每周课外学习时间低于对照组(t=2.093,P=0.038),差异均有统计学意义。(2)近视知识掌握程度:2组干预后近视知识答题得分均较干预前升高(t_(对照组)=5.576、t_(观察组)=11.626,均P=0.000),干预后2组比较,观察组得分高于对照组(t=4.350,P=0.000),差异均有统计学意义。(3)裸眼视力:对照组干预后裸眼视力较干预前降低(t=3.310,P=0.001),观察组干预后裸眼视力较干预前升高(t=5.118,P=0.000),差异均有统计学意义。干预后2组比较,观察组裸眼视力优于对照组(t=5.109,P=0.000),差异均有统计学意义。(4)屈光度:对照组干预后屈光度较本组干预前升高,差异有统计学意义(t=4.176,P=0.000),观察组干预后屈光度较干预前比较,差异无统计学意义(P>0.05);干预后2组比较,观察组屈光度优于对照组,差异有统计学意义(t=2.092,P=0.037)。结论耳穴压丸、梅花针、眼部刮痧及个性化健康教育的中医护理方案在一定程度上能延缓青少年低度近视的进展。